Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 / 2 Single Arm Study of T-cells Expressing Anti-CD19 Chimeric Antigen Receptor in Pediatric and Young Adult Patients With B-cell Malignancies

NCT02772198 is registered in ClinicalTrials.gov with Sheba Medical Center as lead sponsor.

NCT NCT02772198
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02772198 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 / 2 Single Arm Study of T-cells Expressing Anti-CD19 Chimeric Antigen Receptor in Pediatric and Young Adult Patients With B-cell Malignancies
Lead sponsor
Sheba Medical Center
Phase
Phase 1/2
Overall status
Unknown status
Start date
November 30, 2016
Completion date
November 30, 2022
Enrollment
300 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, b-precursor, non-hodgkin lymphoma, b-cell